Novel cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
AssigneeCnpharm Co., Ltd.
InventorsYoun Soo Sohn, Yong Joo Jun, Prakash Gouda Avaji
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new class of cationic linear polyphosphazenes bearing as side groups a hydrophilic poly(ethylene glycol) and a spacer group selected from the group consisting of lysine, oligopeptides containing lysine, amino-ethanol, amino-propanol, amino-butanol, amino-pentanol and amino-hexanol, and the polyphosphazene-drug conjugates comprising hydrophobic anticancer drugs by covalent bonding and the preparation methods thereof. The present polyphosphazene-drug conjugates exhibit outstanding tumor selectivity and low toxicity.
Claims2
(canceled)
A method for delivering an anticancer drug to a patient in need thereof, said method comprising administering to said patient a linear polyphosphazene-drug conjugate compound represented by the following chemical formula 2:
- wherein, in chemical formula 2, n is an integer from 3 to 300;
- MPEG represents methoxy poly(ethylene glycol) with a molecular weight of 350 to 1000;
- S is a spacer group selected from the group consisting of lysine, arginine, glutamine, asparagine, tyrosine, lysine-containing oligopeptide, arginine-containing oligopeptide, glutamine-containing oligopeptide, asparagine-containing oligopeptide, tyrosine containing oligopeptide, amino-ethanol, amino-propanol, amino-butanol, amino-pentanol, and amino-hexanol;
- L is a linker to connect the spacer group and drug molecule D, wherein drug molecule D is an hydrophobic anticancer drug having at least one functional group of hydroxyl or amine;
- x and y are independently in the range of 0-0.5;
- z is in the range of 0-1;
- and
- x+y+z=1.
Dependencies are inferred from the claim text.